miR-130a |
Forward: 5′-ACACTCCAGCTGGGGCTCTTTTCACATTGT-3′ |
Reverse: 5′-CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGAGTAGCAC-3′ |
U6 |
Forward: 5′-CTCGCTTCGGCAGCACA-3′ |
Reverse: 5′-AACGCTTCACGAATTTGCGT-3′ |
Glial fibrillary acidic protein (GFAP) |
Forward: 5′- GCTAATGACTATCGCCGCCAACT-3′ |
Reverse: 5′-CTCCTTAATGACCTCGCCATCCC-3′ |
Heat shock protein 27 (HSP27) |
Forward: 5′-ACGAAGAAAGGCAGGATGAA-3′ |
Reverse: 5′-GCTCCAGACTGTTCCGACTC-3′ |
Dopamine- and cAMP-regulated phosphoprotein (DARPP-32) |
Forward: 5′-AGTTAGGGGAGCTTCG-3′ |
Reverse: 5′-AGTTTCCATCTCTCTGGG-3′ |
Peripheral benzodiazepine receptor (PBR_ |
Forward: 5′-TCCTGCTTTCATGACCATTGGGC-3′ |
Reverse: 5′-ACAACTGTCCCCGCATGGGACTTAG-3′ |
p75 neurotrophin receptor (p75NTR) |
Forward: 5′-AGGGATGGCGTGACTTTC-3′ |
Reverse: 5′-GTTGGCTTCAGGCTTATGC-3′ |
B-cell lymphoma 2-associated X protein (Bax) |
Forward: 5′-CCCTGTGCACTAAAGTGCCCC-3′ |
Reverse: 5′-GTCAGATGGACACATGGTG-3′ |
B-cell lymphoma 2 (Bcl2) |
Forward: 5′-CTACGAGTGGGATGCTGGAGG-3′ |
Reverse: 5′-GTCAGATGGACACATGGTG-3′ |
B-cell lymphoma-extra large (Bcl-XL) |
Forward: 5′-GATCCCCATGGCAGCAGTAAAGCAAG-3′ |
Reverse: 5′- CCCCATCCCGGAAGAGTTCATTCACT-3′ |
β-Actin |
Forward: 5′-GGTCGGTGTGAACGGATTTGG-3′ |
Reverse: 5′-ATGTAGGCCATGAGGTCCACC-3′ |